If you'd invested in: AstraZeneca and Mitie Group

If only...

Pharmaceutical giant AstraZeneca (LSE: AZN) is expected to grow its earnings per share (EPS) in 2018, after four years of stagnant profits. Last month Astra reported that drug sales fell by 2% to $10bn (in constant currency terms) in the first half of 2018, while core operating profits were down 34% to $2.2bn. However, sales from new medicines rose by 69%, thanks largely to a strong performance from its cancer drugs including Tagrisso, which has benefited from its recent approval as the first-choice treatment for lung-cancer patients in Europe.

Be glad you didn't buy...

Mitie Group (LSE: MTO) provides services to owners and occupiers of commercial and industrial properties. The outsourcer, which was hit by several profit warnings and investigations by financial regulators last year, came under scrutiny after Carillion's collapse in January this year. However, in June it reported a pre-tax loss of £24.7m, down from £58.2m the previous year, while revenues rose 3.8% to £2.2bn. Mitie's chief executive Phil Bentley claims the firm's turnaround is on track and that it will return to profit this year as cost saving measures start to take effect.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Explore More

Alice grew up in Stockholm and studied at the University of the Arts London, where she gained a first-class BA in Journalism. She has written for several publications in Stockholm and London, and joined MoneyWeek in 2017.

Alice is now Consumer Editor at The Sun and covers everything from energy bills to Social Security.